Candidate biomarkers in heart failure with reduced and preserved ejection fraction

Abstract

Context: Patients presenting with heart failure symptoms are categorized into heart failure (HF) with reduced and preserved ejection fraction.

Objective: Aim is to investigate the additional use of candidate biomarkers to characterize patients with either sub-type of HF.

Methods: Literature search was conducted in the electronic databases MEDLINE and Cochrane Central Register of Controlled Trials from inception through November 2014.

Results: The results of 47 diseased and general population cohorts were included.

Conclusion: Current studies could outline the additional use of candidate biomarkers especially GDF-15, MR-proADM and high-sensitive determined troponin, although major outcome studies are still missing.

• Growth-differentiation factor 15
• heart failure with reduced and preserved ejection fraction
• highly sensitive determined troponin
• soluble source of tumorigenicity 2

Declaration of interest

Stefan Blankenberg has received honoraria from Abbott Diagnostics, Siemens, Thermo Fisher, and Roche Diagnostics and is a consultant for Thermo Fisher. All other co-authors do not report any conflict of interest.